

[CLAIMS]

1. ~~A composition for use in mobilizing mesenchymal stem cells into peripheral blood, which comprises~~ Use of a peptide selected from the following ~~in manufacture of a medicament or a reagent for mobilizing mesenchymal stem cells into peripheral blood:~~

(a) a peptide consisting of a portion of the amino acid sequence of SEQ ID NO: 1, and comprising the amino acid sequence of SEQ ID NO: 17 or 19;

(b) a peptide consisting of all or a portion of an amino acid sequence resulting from substitution, deletion, insertion, or addition of one to five amino acids in the amino acid sequence of SEQ ID NO: 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 17 or 19; and

(c) a peptide consisting of all or a portion of an amino acid sequence having a sequence identity of 90% or higher with the amino acid sequence of SEQ ID NO: 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 17 or 19.

2. ~~A composition for use in treatment of a disease or pathological condition in a subject by mobilizing mesenchymal stem cells into peripheral blood, which comprises~~ Use of a peptide selected from the following ~~in manufacture of a medicament for treating a disease or pathological condition in a subject by mobilizing mesenchymal stem cells into peripheral blood:~~

(a) a peptide consisting of a portion of the amino acid sequence of SEQ ID NO: 1, and comprising the amino acid sequence of SEQ ID NO: 17 or 19;

(b) a peptide consisting of all or a portion of an amino acid sequence resulting from substitution, deletion, insertion, or addition of one to five amino acids in the amino acid sequence of SEQ ID NO: 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 17 or 19; and

(c) a peptide consisting of all or a portion of an amino acid sequence having a sequence identity of 90% or higher with the amino acid sequence of SEQ ID NO: 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 17 or 19.

3. The ~~composition-use~~ of claim 2, wherein the treatment of a disease or pathological condition is selected from inflammation-suppressing therapy, immunomodulatory therapy, tissue regeneration-inducing therapy, and tissue fibrosis-suppressing therapy.

4. The ~~composition-use~~ of claim 2, wherein the disease or pathological condition is selected from an inflammatory disease, an autoimmune disease, a disease accompanied by tissue damage, ischemia, or necrosis, and a fibrotic disease.

5. The ~~composition-use~~ of claim 2, wherein the disease or pathological condition is inflammatory bowel disease.

6. The ~~composition-use~~ of claim 2, wherein the disease or pathological condition is ulcerative colitis.

7. The ~~composition-use~~ of claim 2, wherein the disease or pathological condition is atopic dermatitis.

8. The ~~composition-use~~ of claim 2, wherein the disease or pathological condition is cerebral infarction.

9. ~~A composition for use in treatment of a disease selected from inflammatory bowel disease, atopic dermatitis, and cerebral infarction, which comprises~~Use of a peptide selected from the following ~~in manufacture of a medicament for treating a disease selected from inflammatory bowel disease, atopic dermatitis, and cerebral infarction:~~

(a) a peptide consisting of a portion of the amino acid sequence of SEQ ID NO: 1, and comprising the amino acid sequence of SEQ ID NO: 17 or 19;

(b) a peptide consisting of all or a portion of an amino acid sequence resulting from substitution, deletion, insertion, or addition of one to five amino acids in the amino acid sequence of SEQ ID NO: 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 17 or 19; and

(c) a peptide consisting of all or a portion of an amino acid sequence having a sequence identity of 90% or higher with the amino acid sequence of SEQ ID NO: 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 17 or 19.

10. A peptide selected from the following:

(a) a peptide consisting of a portion of the amino acid sequence of SEQ ID NO: 1, and comprising the amino acid sequence of SEQ ID NO: 17 or 19;

(b) a peptide consisting of all or a portion of an amino acid sequence resulting from substitution, deletion, insertion, or addition of one to five amino acids in the amino acid sequence of SEQ ID NO: 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 17 or 19; and

(c) a peptide consisting of all or a portion of an amino acid sequence having a sequence identity of 90% or higher with the amino acid sequence of SEQ ID NO: 1, wherein the peptide

comprises the amino acid sequence of SEQ ID NO: 17 or 19.